NCT03609840View on ClinicalTrials.gov

Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Hematologic MalignanciesNonmalignant DiseasesImmune DeficiencyHemoglobinopathiesGenetic Inborn Errors of MetabolismFanconi AnemiaThalassemiaSickle Cell Disease
Interventions
DRUG

Thiotepa

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03609840 - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | Biotech Hunter | Biotech Hunter